Literature DB >> 27376168

Challenges faced in long term ventricular assist device support.

Hirohisa Ikegami1, Paul Kurlansky1, Koji Takeda1, Yoshifumi Naka1.   

Abstract

INTRODUCTION: The development of ventricular assist device (VAD) has been one of the revolutionary advancements in end-stage heart failure management. Although the device has developed and improved significantly over the last few decades, we still face multiple challenges. AREAS COVERED: This review will discuss quality of life, survival, and clinically encountered complications in patients with VAD support. The literature was extensively reviewed for studies describing the above topic area. We describe the impact of major challenges faced in VAD support and discuss their future and expectations. Expert commentary: The technological advancement of VADs has contributed to major improvement of overall survival, enhancement of quality of life and decrease of incidence of complications. It is expected that technologies will continue to evolve. At the same time, the indications for and timing of device implantation, and selection of device type are continuously important in clinical practice setting.

Entities:  

Keywords:  End-stage heart failure; complications; long term; mechanical cardiac support; outcome; postoperative management; ventricular assist device

Mesh:

Year:  2016        PMID: 27376168     DOI: 10.1080/17434440.2016.1208557

Source DB:  PubMed          Journal:  Expert Rev Med Devices        ISSN: 1743-4440            Impact factor:   3.166


  1 in total

1.  Decoupling Between Diastolic Pulmonary Artery Pressure and Pulmonary Capillary Wedge Pressure as a Prognostic Factor After Continuous Flow Ventricular Assist Device Implantation.

Authors:  Teruhiko Imamura; Ben Chung; Ann Nguyen; Daniel Rodgers; Gabriel Sayer; Sirtaz Adatya; Nitasha Sarswat; Gene Kim; Jayant Raikhelkar; Takeyohi Ota; Tae Song; Colleen Juricek; Viktoriya Kagan; Valluvan Jeevanandam; Mandeep Mehra; Daniel Burkhoff; Nir Uriel
Journal:  Circ Heart Fail       Date:  2017-09       Impact factor: 8.790

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.